Noemie Wald - 1Iteos therapeutics | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 17 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A novel plasma cell-based mechanism of action of adenosine immunomodulation and A2AR antagonism

Chiara Martinoli,Paola Tieppo,Marjorie Mercier,Hussein Shehade,Noemie Wald, Anais Vezzu,Annelise Hermant, Boris Pirlot,Stephanie Ma,Maurizio Ceppi,Yvonne McGrath, Maura Rossetti

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

74 A-Tigit Mab Belrestotug in Combination with Anti-Pd1 Induces an Immunocompetent Tumor Microenvironment (TME)

Maurizio Ceppi,Gregory Driessens,Bart Claes,Stephanie Ma,Olivier De Henau,Julia Cuende,Iain Welsby, Nicolas Rosewick,Noemie Wald, Anais Vezzu,Marjorie Mercier,Paola Tieppo,Yvonne McGrath,Marion Libouban

Regular and Young Investigator Award Abstracts (2023)

引用0浏览0引用

Abstract LB189: Pharmacodynamic Assessment of A-Tigit Mab EOS-448 Highlights Multiple FcγR-mediated Mode-of-actions in Blood and Tumor of Patients with Advanced Solid Tumors

Julia Cuende,Julie Preillon,Noemie Wald,Marjorie Mercier,Paola Tieppo,Iain Welsby,Veronique Bodo,Yvonne McGrath,Tom F. Van Den Mooter,Jean-Pascal Machiels, Clarisse Truong,Olivier De Henau,Gregory Driessens,Marion Libouban

Cancer researchno. 12_Supplement (2022): LB189-LB189

引用0浏览0引用

Pharmacodynamic assessment of a-TIGIT mAb EOS-448 highlights multiple FcR-mediated mode-of-actions in blood and tumor of patients with advanced solid tumors

CANCER RESEARCH（2022）

引用0浏览0引用

Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor

Laurence Buisseret,Sylvie Rottey,Johann S. De Bono,Ariane Migeotte,Brant Delafontaine,Thubeena Manickavasagar,Chiara Martinoli,Noemie Wald, Maura Rossetti,Esha A. Gangolli,Erol Wiegert,Nicola McIntyre,Joanne J. Lager,Jean-Pascal H. Machiels

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用12浏览0引用

Abstract 3161: Preparation of Aclinical Trial with A-Tigit Antagonist Antibody EOS884448, Which Demonstrates Potent Preclinical Activity and Safe Toxicology Profile

Thi Lien-Anh Nguyen,Julia Cuende,Julie Preillon,Lucile Garnero,Virginie Rabolli,Noemie Wald,Catherine Hoofd, Patricia Chevron,Marjorie Mercier,Olivier De Henau,Veronique Bodo,Gregory Driessens

Cancer research（2020）

引用2浏览0引用

Phenotyping of TIGIT pathway members may be used for cancer selection in the clinical application of anti-TIGIT antibody EOS884448

Noemie Wald,Julia Cuende,Marjorie Mercier,Florence Nyawouame,Margreet Brouwer,Erica Houthuys,Gregory Driessens,Veronique Bodo,Catherine Hoofd

JOURNAL FOR IMMUNOTHERAPY OF CANCER（2019）

引用0浏览0引用

Abstract 4969: TIGIT pathway phenotyping sheds light on promising strategies to restore anti-tumor immunity

Noémie Wald,Marjorie Mercier,Julia Cuende,Florence Nyawouame,Shruthi Prasad,Margreet Brouwer,Erica Houthuys,Anne Marie-Cardine,Martine Bagot,Grégory Driessens,Véronique Bodo,Catherine Hoofd

Immunology（2019）

引用1浏览0引用

Abstract 4154: EOS100850 Inhibits A2A Receptor Signaling in Human Whole Blood: Two Pharmacodynamic Assays to Monitor EOS100850 Activity in Clinical Studies

Chiara Martinoli,Margreet Brouwer,Erica Houthuys,Marjorie Mercier,Noemie Wald,Bruno Gomes,Stefano Crosignani,Veronique Bodo

Clinical Research (Excluding Clinical Trials)（2019）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn